Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$65.0b

Regeneron Pharmaceuticals Valuation

Is REGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$1.83k
Fair Value
66.9% undervalued intrinsic discount
24
Number of Analysts

Below Fair Value: REGN ($604.62) is trading below our estimate of fair value ($1826.97)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGN?

Key metric: As REGN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REGN. This is calculated by dividing REGN's market cap by their current earnings.
What is REGN's PE Ratio?
PE Ratio14.2x
EarningsUS$4.50b
Market CapUS$64.96b

Price to Earnings Ratio vs Peers

How does REGN's PE Ratio compare to its peers?

The above table shows the PE ratio for REGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.2x
GILD Gilead Sciences
22.5x11.08%US$135.7b
AMGN Amgen
24.6x11.96%US$147.9b
BIIB Biogen
12.6x9.09%US$19.1b
ABBV AbbVie
77.3x26.28%US$326.5b
REGN Regeneron Pharmaceuticals
14.2x7.44%US$65.0b

Price-To-Earnings vs Peers: REGN is good value based on its Price-To-Earnings Ratio (14.2x) compared to the peer average (34.2x).

Price to Earnings Ratio vs Industry

How does REGN's PE Ratio compare vs other companies in the US Biotechs Industry?

14 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AGIO Agios Pharmaceuticals
2.6x-23.07%US$1.75b
NVAX Novavax
2.4x-45.35%US$1.24b
INBX Inhibrx Biosciences
0.1x-148.50%US$189.20m
CHRS Coherus BioSciences
1.8x-21.60%US$94.61m
REGN 14.2xIndustry Avg. 16.0xNo. of Companies14PE01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: REGN is good value based on its Price-To-Earnings Ratio (14.2x) compared to the US Biotechs industry average (16x).

Price to Earnings Ratio vs Fair Ratio

What is REGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.2x
Fair PE Ratio25.4x

Price-To-Earnings vs Fair Ratio: REGN is good value based on its Price-To-Earnings Ratio (14.2x) compared to the estimated Fair Price-To-Earnings Ratio (25.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$604.62
US$797.21
+31.85%
15.10%US$958.00US$535.00n/a24
May ’26US$590.00
US$802.21
+35.97%
15.92%US$979.00US$535.00n/a24
Apr ’26US$617.00
US$916.63
+48.56%
15.64%US$1,152.00US$575.00n/a24
Mar ’26US$698.74
US$926.66
+32.62%
15.49%US$1,152.00US$575.00n/a25
Feb ’26US$672.98
US$968.01
+43.84%
16.82%US$1,200.00US$565.00n/a25
Jan ’26US$712.33
US$1,053.08
+47.84%
15.51%US$1,230.00US$565.00n/a24
Dec ’25US$750.22
US$1,078.63
+43.78%
12.85%US$1,230.00US$800.00n/a25
Nov ’25US$843.60
US$1,095.43
+29.85%
11.06%US$1,230.00US$800.00n/a25
Oct ’25US$1,046.91
US$1,157.67
+10.58%
11.74%US$1,300.00US$820.00n/a25
Sep ’25US$1,184.69
US$1,153.33
-2.65%
11.96%US$1,300.00US$805.00n/a25
Aug ’25US$1,093.14
US$1,119.01
+2.37%
12.86%US$1,300.00US$720.00n/a25
Jul ’25US$1,057.02
US$1,056.41
-0.058%
12.07%US$1,229.00US$720.00n/a25
Jun ’25US$980.16
US$1,047.65
+6.89%
11.73%US$1,185.00US$720.00n/a25
May ’25US$903.48
US$1,038.08
+14.90%
11.20%US$1,189.00US$720.00US$590.0025
Apr ’25US$969.31
US$1,022.19
+5.46%
11.32%US$1,184.00US$710.00US$617.0025
Mar ’25US$982.82
US$1,009.93
+2.76%
11.85%US$1,184.00US$710.00US$698.7423
Feb ’25US$957.78
US$968.35
+1.10%
11.75%US$1,125.00US$710.00US$672.9824
Jan ’25US$878.29
US$919.76
+4.72%
11.59%US$1,125.00US$700.00US$712.3324
Dec ’24US$814.86
US$908.57
+11.50%
10.72%US$1,066.00US$680.00US$750.2225
Nov ’24US$791.27
US$902.36
+14.04%
10.64%US$1,064.00US$680.00US$843.6023
Oct ’24US$822.96
US$898.87
+9.22%
10.50%US$1,050.00US$680.00US$1,046.9123
Sep ’24US$831.63
US$895.61
+7.69%
10.76%US$1,050.00US$665.00US$1,184.6923
Aug ’24US$739.07
US$857.78
+16.06%
10.64%US$1,045.00US$650.00US$1,093.1423
Jul ’24US$718.54
US$862.87
+20.09%
11.69%US$1,045.00US$650.00US$1,057.0223
Jun ’24US$731.17
US$883.78
+20.87%
10.87%US$1,050.00US$650.00US$980.1623
May ’24US$806.72
US$878.61
+8.91%
10.52%US$1,040.00US$650.00US$903.4823
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
US$797.21
Fair Value
24.2% undervalued intrinsic discount
24
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 04:14
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 63 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research